Elixxer Stock Current Valuation
| ELXR Stock | CAD 1.15 0.00 0.00% |
Valuation analysis of Elixxer helps investors to measure Elixxer's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At this time, Elixxer's Total Cashflows From Investing Activities is fairly stable compared to the past year. Other Cashflows From Financing Activities is likely to climb to about 308.1 K in 2024, whereas Cash is likely to drop slightly above 55.9 K in 2024. Fundamental drivers impacting Elixxer's valuation include:
Price Book 2.669 | Enterprise Value 21.9 M | Enterprise Value Ebitda (2.63) | Price Sales 767.8 K | Enterprise Value Revenue 113.5261 |
Fairly Valued
Today
Please note that Elixxer's price fluctuation is very steady at this time. Calculation of the real value of Elixxer is based on 3 months time horizon. Increasing Elixxer's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Elixxer stock is determined by what a typical buyer is willing to pay for full or partial control of Elixxer. Since Elixxer is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Elixxer Stock. However, Elixxer's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.15 | Real 1.15 | Hype 1.15 | Naive 1.15 |
The intrinsic value of Elixxer's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Elixxer's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Elixxer helps investors to forecast how Elixxer stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Elixxer more accurately as focusing exclusively on Elixxer's fundamentals will not take into account other important factors: Elixxer Company Current Valuation Analysis
Elixxer's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Elixxer Current Valuation | 21.92 M |
Most of Elixxer's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Elixxer is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Elixxer has a Current Valuation of 21.92 M. This is 99.85% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current valuation for all Canada stocks is 99.87% higher than that of the company.
Elixxer Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Elixxer's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Elixxer could also be used in its relative valuation, which is a method of valuing Elixxer by comparing valuation metrics of similar companies.Elixxer is currently under evaluation in current valuation category among its peers.
Elixxer Fundamentals
| Return On Equity | -10.14 | ||||
| Return On Asset | -0.3 | ||||
| Current Valuation | 21.92 M | ||||
| Shares Outstanding | 11.34 M | ||||
| Shares Owned By Institutions | 32.04 % | ||||
| Number Of Shares Shorted | 238 | ||||
| Price To Book | 2.67 X | ||||
| Price To Sales | 767,774 X | ||||
| Revenue | 82.13 K | ||||
| Gross Profit | 42.41 K | ||||
| EBITDA | (2.5 M) | ||||
| Net Income | (6.17 M) | ||||
| Cash And Equivalents | 969.92 K | ||||
| Total Debt | 4.41 M | ||||
| Debt To Equity | 1.96 % | ||||
| Current Ratio | 0.06 X | ||||
| Book Value Per Share | (0.76) X | ||||
| Cash Flow From Operations | (2.35 M) | ||||
| Short Ratio | 0.67 X | ||||
| Earnings Per Share | (1.02) X | ||||
| Beta | 0.87 | ||||
| Market Capitalization | 13.05 M | ||||
| Total Asset | 5.37 M | ||||
| Retained Earnings | (80.5 M) | ||||
| Working Capital | (4.81 M) | ||||
| Net Asset | 5.37 M |
About Elixxer Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Elixxer's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Elixxer using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Elixxer based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Elixxer Stock Analysis
When running Elixxer's price analysis, check to measure Elixxer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elixxer is operating at the current time. Most of Elixxer's value examination focuses on studying past and present price action to predict the probability of Elixxer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elixxer's price. Additionally, you may evaluate how the addition of Elixxer to your portfolios can decrease your overall portfolio volatility.